When we launched the CoMMPass Study in 2011, we saw a future where multiple myeloma patients are precisely treated based on their genetic mutations and other unique aspects of their cancer. This lifesaving approach to treatment, known as Precision Medicine, is now reality.

Through CoMMpass, we learned that multiple myeloma is not just one disease. Multiple myeloma is made up of at least 12 different sub-types, each of which is defined by specific genetic mutations and other abnormalities that affect how the disease responds to specific treatments.

The MyDRUG (Myeloma – Developing Regimens Using Genomics) clinical trial turns these learnings into action. Conducted by the MMRF and led by Dr. Shaji Kumar of the Mayo Clinic in Rochester, Minn., this groundbreaking cancer research study will test drugs designed specifically for each sub-type, greatly improving the odds that the treatment will be beneficial.

Unlike traditional clinical trials, which test one drug or a single combination of drugs, the MyDRUG clinical trial studies the impact of several different drugs that target the genetic mutations and other molecular abnormalities identified in CoMMpass. This kind of clinical trial, known as a platform study, not only has the potential to accelerate the speed by which new treatments are tested, it also more efficiently matches patients to treatments that are most likely to work. It is the first and only clinical trial of its kind in multiple myeloma.

MMRF’s MyDRUG Platform Trial Aims For Efficiency In Testing Treatments For Myeloma Mutations

The Multiple Myeloma Research Foundation (MMRF) has initiated the first-ever platform trial for multiple myeloma, MyDRUG, to test drugs that are approved or in late-stage development for other cancers, but haven’t been tested in myeloma.